Listed

Indivior Pharmaceuticals, Inc.

INDVNasdaqCIK 1625297HealthcareFiscal year ends Dec 31

Latest reported revenue, Q3 FY2026$356.0mRevenue, Q3 FY2026, three months to 2026-09-30$356.0m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-10-29, accession 0001628280-26-068013.Report this figureThree months to Sep 30, 2026, from the 10-Q filed Oct 29, 2026.

Latest quarter: Q3 FY2026

Three months to Sep 30, 2026, against the same quarter a year earlier.

  • Revenue$356.0mRevenue, Q3 FY2026, three months to 2026-09-30$356.0m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-10-29, accession 0001628280-26-068013.Report this figure+13.4% on a year earlier
  • Gross margin85.7%Gross margin, Q3 FY2026, three months to 2026-09-30. gross profit / revenueGross profit: $305.0m. XBRL concept us-gaap:GrossProfit. 10-Q filed 2026-10-29, accession 0001628280-26-068013.Revenue: $356.0m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-10-29, accession 0001628280-26-068013.Report this figure+12.4 pts on a year earlier
  • Operating margin50.6%Operating margin, Q3 FY2026, three months to 2026-09-30. operating income / revenueOperating income: $180.0m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-10-29, accession 0001628280-26-068013.Revenue: $356.0m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-10-29, accession 0001628280-26-068013.Report this figure+36.9 pts on a year earlier
  • Net margin38.5%Net margin, Q3 FY2026, three months to 2026-09-30. net income / revenueNet income: $137.0m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-10-29, accession 0001628280-26-068013.Revenue: $356.0m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-10-29, accession 0001628280-26-068013.Report this figure+25.1 pts on a year earlier
  • Diluted EPS$1.12Diluted EPS, Q3 FY2026, three months to 2026-09-30$1.12 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-10-29, accession 0001628280-26-068013.Report this figure+239.4% on a year earlier
  • Free cash flow$83.0mFree cash flow, Q3 FY2026, three months to 2026-09-30. operating cash flow − capital expenditureOperating cash flow: $97.0m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-10-29, accession 0001628280-26-068013. Derived: 9-month figure less the 6-month figure.Capital expenditure: $14.0m. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2026-10-29, accession 0001628280-26-068013. Derived: 9-month figure less the 6-month figure.Report this figureSign changed from a year earlier

Last eight quarters

Full statements
Revenue$356.0mGross margin 85.7%
Diluted EPS$1.12, Q3 FY2026
Free cash flow$83.0m, Q3 FY2026
Indivior Pharmaceuticals, Inc., key figures for the last eight quarters
Line itemUnitQ4 FY20242024-12-31Q1 FY20252025-03-31Q2 FY20252025-06-30Q3 FY20252025-09-30Q4 FY20252025-12-31Q1 FY20262026-03-31Q2 FY20262026-06-30Q3 FY20262026-09-30Shape over the periods
Revenue$m299Revenue, Q4 FY2024, three months to 2024-12-31$299.0m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-02-26, accession 0001628280-26-012237. Derived: 12-month figure less the 9-month figure.Report this figure266Revenue, Q1 FY2025, three months to 2025-03-31$266.0m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-04-30, accession 0001628280-26-028850.Report this figure302Revenue, Q2 FY2025, three months to 2025-06-30$302.0m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-08-03, accession 0001628280-26-051895.Report this figure314Revenue, Q3 FY2025, three months to 2025-09-30$314.0m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-10-29, accession 0001628280-26-068013.Report this figure358Revenue, Q4 FY2025, three months to 2025-12-31$358.0m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-02-26, accession 0001628280-26-012237. Derived: 12-month figure less the 9-month figure.Report this figure317Revenue, Q1 FY2026, three months to 2026-03-31$317.0m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-04-30, accession 0001628280-26-028850.Report this figure343Revenue, Q2 FY2026, three months to 2026-06-30$343.0m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-08-03, accession 0001628280-26-051895.Report this figure356Revenue, Q3 FY2026, three months to 2026-09-30$356.0m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-10-29, accession 0001628280-26-068013.Report this figure
Gross margin%83.6%Gross margin, Q4 FY2024, three months to 2024-12-31. gross profit / revenueGross profit: $250.0m. XBRL concept us-gaap:GrossProfit. 10-K filed 2026-02-26, accession 0001628280-26-012237. Derived: 12-month figure less the 9-month figure.Revenue: $299.0m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-02-26, accession 0001628280-26-012237. Derived: 12-month figure less the 9-month figure.Report this figure83.1%Gross margin, Q1 FY2025, three months to 2025-03-31. gross profit / revenueGross profit: $221.0m. XBRL concept us-gaap:GrossProfit. 10-Q filed 2026-04-30, accession 0001628280-26-028850.Revenue: $266.0m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-04-30, accession 0001628280-26-028850.Report this figure82.8%Gross margin, Q2 FY2025, three months to 2025-06-30. gross profit / revenueGross profit: $250.0m. XBRL concept us-gaap:GrossProfit. 10-Q filed 2026-08-03, accession 0001628280-26-051895.Revenue: $302.0m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-08-03, accession 0001628280-26-051895.Report this figure73.2%Gross margin, Q3 FY2025, three months to 2025-09-30. gross profit / revenueGross profit: $230.0m. XBRL concept us-gaap:GrossProfit. 10-Q filed 2026-10-29, accession 0001628280-26-068013.Revenue: $314.0m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-10-29, accession 0001628280-26-068013.Report this figure81.6%Gross margin, Q4 FY2025, three months to 2025-12-31. gross profit / revenueGross profit: $292.0m. XBRL concept us-gaap:GrossProfit. 10-K filed 2026-02-26, accession 0001628280-26-012237. Derived: 12-month figure less the 9-month figure.Revenue: $358.0m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-02-26, accession 0001628280-26-012237. Derived: 12-month figure less the 9-month figure.Report this figure87.4%Gross margin, Q1 FY2026, three months to 2026-03-31. gross profit / revenueGross profit: $277.0m. XBRL concept us-gaap:GrossProfit. 10-Q filed 2026-04-30, accession 0001628280-26-028850.Revenue: $317.0m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-04-30, accession 0001628280-26-028850.Report this figure85.7%Gross margin, Q2 FY2026, three months to 2026-06-30. gross profit / revenueGross profit: $294.0m. XBRL concept us-gaap:GrossProfit. 10-Q filed 2026-08-03, accession 0001628280-26-051895.Revenue: $343.0m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-08-03, accession 0001628280-26-051895.Report this figure85.7%Gross margin, Q3 FY2026, three months to 2026-09-30. gross profit / revenueGross profit: $305.0m. XBRL concept us-gaap:GrossProfit. 10-Q filed 2026-10-29, accession 0001628280-26-068013.Revenue: $356.0m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-10-29, accession 0001628280-26-068013.Report this figure
Operating margin%15.4%Operating margin, Q4 FY2024, three months to 2024-12-31. operating income / revenueOperating income: $46.0m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2026-02-26, accession 0001628280-26-012237.Revenue: $299.0m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-02-26, accession 0001628280-26-012237. Derived: 12-month figure less the 9-month figure.Report this figure24.8%Operating margin, Q1 FY2025, three months to 2025-03-31. operating income / revenueOperating income: $66.0m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-04-30, accession 0001628280-26-028850.Revenue: $266.0m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-04-30, accession 0001628280-26-028850.Report this figure23.8%Operating margin, Q2 FY2025, three months to 2025-06-30. operating income / revenueOperating income: $72.0m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-08-03, accession 0001628280-26-051895.Revenue: $302.0m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-08-03, accession 0001628280-26-051895.Report this figure13.7%Operating margin, Q3 FY2025, three months to 2025-09-30. operating income / revenueOperating income: $43.0m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-10-29, accession 0001628280-26-068013.Revenue: $314.0m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-10-29, accession 0001628280-26-068013.Report this figure22.6%Operating margin, Q4 FY2025, three months to 2025-12-31. operating income / revenueOperating income: $81.0m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2026-02-26, accession 0001628280-26-012237. Derived: 12-month figure less the 9-month figure.Revenue: $358.0m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-02-26, accession 0001628280-26-012237. Derived: 12-month figure less the 9-month figure.Report this figure43.2%Operating margin, Q1 FY2026, three months to 2026-03-31. operating income / revenueOperating income: $137.0m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-04-30, accession 0001628280-26-028850.Revenue: $317.0m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-04-30, accession 0001628280-26-028850.Report this figure46.6%Operating margin, Q2 FY2026, three months to 2026-06-30. operating income / revenueOperating income: $160.0m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-08-03, accession 0001628280-26-051895.Revenue: $343.0m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-08-03, accession 0001628280-26-051895.Report this figure50.6%Operating margin, Q3 FY2026, three months to 2026-09-30. operating income / revenueOperating income: $180.0m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-10-29, accession 0001628280-26-068013.Revenue: $356.0m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-10-29, accession 0001628280-26-068013.Report this figure
Net margin%7.0%Net margin, Q4 FY2024, three months to 2024-12-31. net income / revenueNet income: $21.0m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2026-02-26, accession 0001628280-26-012237.Revenue: $299.0m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-02-26, accession 0001628280-26-012237. Derived: 12-month figure less the 9-month figure.Report this figure17.7%Net margin, Q1 FY2025, three months to 2025-03-31. net income / revenueNet income: $47.0m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-10-29, accession 0001628280-26-068013.Revenue: $266.0m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-04-30, accession 0001628280-26-028850.Report this figure6.0%Net margin, Q2 FY2025, three months to 2025-06-30. net income / revenueNet income: $18.0m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-10-29, accession 0001628280-26-068013.Revenue: $302.0m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-08-03, accession 0001628280-26-051895.Report this figure13.4%Net margin, Q3 FY2025, three months to 2025-09-30. net income / revenueNet income: $42.0m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-10-29, accession 0001628280-26-068013.Revenue: $314.0m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-10-29, accession 0001628280-26-068013.Report this figure28.5%Net margin, Q4 FY2025, three months to 2025-12-31. net income / revenueNet income: $102.0m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2026-02-26, accession 0001628280-26-012237. Derived: 12-month figure less the 9-month figure.Revenue: $358.0m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-02-26, accession 0001628280-26-012237. Derived: 12-month figure less the 9-month figure.Report this figure28.1%Net margin, Q1 FY2026, three months to 2026-03-31. net income / revenueNet income: $89.0m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-10-29, accession 0001628280-26-068013.Revenue: $317.0m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-04-30, accession 0001628280-26-028850.Report this figure35.6%Net margin, Q2 FY2026, three months to 2026-06-30. net income / revenueNet income: $122.0m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-10-29, accession 0001628280-26-068013.Revenue: $343.0m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-08-03, accession 0001628280-26-051895.Report this figure38.5%Net margin, Q3 FY2026, three months to 2026-09-30. net income / revenueNet income: $137.0m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-10-29, accession 0001628280-26-068013.Revenue: $356.0m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-10-29, accession 0001628280-26-068013.Report this figure
Diluted EPS$ per sharenot reported (Diluted EPS not reported)0.38Diluted EPS, Q1 FY2025, three months to 2025-03-31$0.38 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-04-30, accession 0001628280-26-028850.Report this figure0.14Diluted EPS, Q2 FY2025, three months to 2025-06-30$0.14 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-08-03, accession 0001628280-26-051895.Report this figure0.33Diluted EPS, Q3 FY2025, three months to 2025-09-30$0.33 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-10-29, accession 0001628280-26-068013.Report this figurenot reported (Diluted EPS not reported)0.69Diluted EPS, Q1 FY2026, three months to 2026-03-31$0.69 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-04-30, accession 0001628280-26-028850.Report this figure0.98Diluted EPS, Q2 FY2026, three months to 2026-06-30$0.98 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-08-03, accession 0001628280-26-051895.Report this figure1.12Diluted EPS, Q3 FY2026, three months to 2026-09-30$1.12 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-10-29, accession 0001628280-26-068013.Report this figure
Free cash flow$m(33.0)Free cash flow, Q4 FY2024, three months to 2024-12-31. operating cash flow − capital expenditureOperating cash flow: −$17.0m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2026-02-26, accession 0001628280-26-012237. Derived: 12-month figure less the 9-month figure.Capital expenditure: $16.0m. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-K filed 2026-02-26, accession 0001628280-26-012237. Derived: 12-month figure less the 9-month figure.Report this figure70.0Free cash flow, Q1 FY2025, three months to 2025-03-31. operating cash flow − capital expenditureOperating cash flow: $75.0m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-04-30, accession 0001628280-26-028850.Capital expenditure: $5.0m. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2026-04-30, accession 0001628280-26-028850.Report this figure141Free cash flow, Q2 FY2025, three months to 2025-06-30. operating cash flow − capital expenditureOperating cash flow: $158.0m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-08-03, accession 0001628280-26-051895. Derived: 6-month figure less the 3-month figure.Capital expenditure: $17.0m. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2026-08-03, accession 0001628280-26-051895. Derived: 6-month figure less the 3-month figure.Report this figure(59.0)Free cash flow, Q3 FY2025, three months to 2025-09-30. operating cash flow − capital expenditureOperating cash flow: −$39.0m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-10-29, accession 0001628280-26-068013. Derived: 9-month figure less the 6-month figure.Capital expenditure: $20.0m. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2026-10-29, accession 0001628280-26-068013. Derived: 9-month figure less the 6-month figure.Report this figure(245)Free cash flow, Q4 FY2025, three months to 2025-12-31. operating cash flow − capital expenditureOperating cash flow: −$221.0m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2026-02-26, accession 0001628280-26-012237. Derived: 12-month figure less the 9-month figure.Capital expenditure: $24.0m. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-K filed 2026-02-26, accession 0001628280-26-012237. Derived: 12-month figure less the 9-month figure.Report this figure(29.0)Free cash flow, Q1 FY2026, three months to 2026-03-31. operating cash flow − capital expenditureOperating cash flow: −$9.0m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-04-30, accession 0001628280-26-028850.Capital expenditure: $20.0m. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2026-04-30, accession 0001628280-26-028850.Report this figure222Free cash flow, Q2 FY2026, three months to 2026-06-30. operating cash flow − capital expenditureOperating cash flow: $229.0m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-08-03, accession 0001628280-26-051895. Derived: 6-month figure less the 3-month figure.Capital expenditure: $7.0m. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2026-08-03, accession 0001628280-26-051895. Derived: 6-month figure less the 3-month figure.Report this figure83.0Free cash flow, Q3 FY2026, three months to 2026-09-30. operating cash flow − capital expenditureOperating cash flow: $97.0m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-10-29, accession 0001628280-26-068013. Derived: 9-month figure less the 6-month figure.Capital expenditure: $14.0m. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2026-10-29, accession 0001628280-26-068013. Derived: 9-month figure less the 6-month figure.Report this figure

Focus or hover a figure to see its XBRL concept, period and filing; each links to that filing. A figure marked d is derived: a quarter computed from year-to-date figures, such as the fourth quarter as the fiscal year less the nine months before it. A ratio reads not reported when any input is missing.

Last five fiscal years

Revenue$1.24bnGross margin 80.2%
Diluted EPS$1.64, FY2025
Free cash flow−$93.0m, FY2025
Indivior Pharmaceuticals, Inc., key figures for the last five fiscal years
Line itemUnitFY2021-12-31FY2022-12-31FY20232023-12-31FY20242024-12-31FY20252025-12-31Shape over the periods
Revenue$m791Revenue, period not labelled, twelve months to 2021-12-31$791.0m. XBRL concept ifrs-full:RevenueFromContractsWithCustomers. 20-F filed 2024-03-06, accession 0001625297-24-000017.Report this figure901Revenue, period not labelled, twelve months to 2022-12-31$901.0m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2025-03-03, accession 0001625297-25-000016.Report this figure1,093Revenue, FY2023, twelve months to 2023-12-31$1.09bn. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-02-26, accession 0001628280-26-012237.Report this figure1,188Revenue, FY2024, twelve months to 2024-12-31$1.19bn. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-02-26, accession 0001628280-26-012237.Report this figure1,239Revenue, FY2025, twelve months to 2025-12-31$1.24bn. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-02-26, accession 0001628280-26-012237.Report this figure
Gross margin%83.9%Gross margin, period not labelled, twelve months to 2021-12-31. gross profit / revenueGross profit: $664.0m. XBRL concept ifrs-full:GrossProfit. 20-F filed 2024-03-06, accession 0001625297-24-000017.Revenue: $791.0m. XBRL concept ifrs-full:RevenueFromContractsWithCustomers. 20-F filed 2024-03-06, accession 0001625297-24-000017.Report this figure83.1%Gross margin, period not labelled, twelve months to 2022-12-31. gross profit / revenueGross profit: $749.0m. XBRL concept us-gaap:GrossProfit. 10-K filed 2025-03-03, accession 0001625297-25-000016.Revenue: $901.0m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2025-03-03, accession 0001625297-25-000016.Report this figure84.1%Gross margin, FY2023, twelve months to 2023-12-31. gross profit / revenueGross profit: $919.0m. XBRL concept us-gaap:GrossProfit. 10-K filed 2026-02-26, accession 0001628280-26-012237.Revenue: $1.09bn. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-02-26, accession 0001628280-26-012237.Report this figure80.6%Gross margin, FY2024, twelve months to 2024-12-31. gross profit / revenueGross profit: $957.0m. XBRL concept us-gaap:GrossProfit. 10-K filed 2026-02-26, accession 0001628280-26-012237.Revenue: $1.19bn. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-02-26, accession 0001628280-26-012237.Report this figure80.2%Gross margin, FY2025, twelve months to 2025-12-31. gross profit / revenueGross profit: $994.0m. XBRL concept us-gaap:GrossProfit. 10-K filed 2026-02-26, accession 0001628280-26-012237.Revenue: $1.24bn. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-02-26, accession 0001628280-26-012237.Report this figure
Operating margin%26.9%Operating margin, period not labelled, twelve months to 2021-12-31. operating income / revenueOperating income: $213.0m. XBRL concept ifrs-full:ProfitLossFromOperatingActivities. 20-F filed 2024-03-06, accession 0001625297-24-000017.Revenue: $791.0m. XBRL concept ifrs-full:RevenueFromContractsWithCustomers. 20-F filed 2024-03-06, accession 0001625297-24-000017.Report this figure(8.5%)Operating margin, period not labelled, twelve months to 2022-12-31. operating income / revenueOperating income: −$77.0m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2025-10-30, accession 0001628280-25-047530.Revenue: $901.0m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2025-03-03, accession 0001625297-25-000016.Report this figure(13.9%)Operating margin, FY2023, twelve months to 2023-12-31. operating income / revenueOperating income: −$152.0m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2026-02-26, accession 0001628280-26-012237.Revenue: $1.09bn. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-02-26, accession 0001628280-26-012237.Report this figure3.2%Operating margin, FY2024, twelve months to 2024-12-31. operating income / revenueOperating income: $38.0m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2026-02-26, accession 0001628280-26-012237.Revenue: $1.19bn. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-02-26, accession 0001628280-26-012237.Report this figure21.1%Operating margin, FY2025, twelve months to 2025-12-31. operating income / revenueOperating income: $262.0m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2026-02-26, accession 0001628280-26-012237.Revenue: $1.24bn. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-02-26, accession 0001628280-26-012237.Report this figure
Net margin%25.9%Net margin, period not labelled, twelve months to 2021-12-31. net income / revenueNet income: $205.0m. XBRL concept ifrs-full:ProfitLoss. 20-F filed 2024-03-06, accession 0001625297-24-000017.Revenue: $791.0m. XBRL concept ifrs-full:RevenueFromContractsWithCustomers. 20-F filed 2024-03-06, accession 0001625297-24-000017.Report this figure(4.7%)Net margin, period not labelled, twelve months to 2022-12-31. net income / revenueNet income: −$42.0m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2025-10-30, accession 0001628280-25-047530.Revenue: $901.0m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2025-03-03, accession 0001625297-25-000016.Report this figure(11.5%)Net margin, FY2023, twelve months to 2023-12-31. net income / revenueNet income: −$126.0m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2026-02-26, accession 0001628280-26-012237.Revenue: $1.09bn. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-02-26, accession 0001628280-26-012237.Report this figure0.6%Net margin, FY2024, twelve months to 2024-12-31. net income / revenueNet income: $7.0m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2026-02-26, accession 0001628280-26-012237.Revenue: $1.19bn. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-02-26, accession 0001628280-26-012237.Report this figure16.9%Net margin, FY2025, twelve months to 2025-12-31. net income / revenueNet income: $210.0m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2026-02-26, accession 0001628280-26-012237.Revenue: $1.24bn. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-02-26, accession 0001628280-26-012237.Report this figure
Diluted EPS$ per sharenot reported (Diluted EPS not reported)(0.30)Diluted EPS, period not labelled, twelve months to 2022-12-31−$0.30 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2025-10-30, accession 0001628280-25-047530.Report this figure(0.92)Diluted EPS, FY2023, twelve months to 2023-12-31−$0.92 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-K filed 2026-02-26, accession 0001628280-26-012237.Report this figure0.05Diluted EPS, FY2024, twelve months to 2024-12-31$0.05 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-K filed 2026-02-26, accession 0001628280-26-012237.Report this figure1.64Diluted EPS, FY2025, twelve months to 2025-12-31$1.64 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-K filed 2026-02-26, accession 0001628280-26-012237.Report this figure
Free cash flow$m349Free cash flow, period not labelled, twelve months to 2021-12-31. operating cash flow − capital expenditureOperating cash flow: $353.0m. XBRL concept ifrs-full:CashFlowsFromUsedInOperatingActivities. 20-F filed 2024-03-06, accession 0001625297-24-000017.Capital expenditure: $4.0m. XBRL concept ifrs-full:PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities. 20-F filed 2024-03-06, accession 0001625297-24-000017.Report this figure(9.0)Free cash flow, period not labelled, twelve months to 2022-12-31. operating cash flow − capital expenditureOperating cash flow: −$4.0m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2025-10-30, accession 0001628280-25-047530.Capital expenditure: $5.0m. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-K filed 2025-03-03, accession 0001625297-25-000016.Report this figure(308)Free cash flow, FY2023, twelve months to 2023-12-31. operating cash flow − capital expenditureOperating cash flow: −$300.0m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2026-02-26, accession 0001628280-26-012237.Capital expenditure: $8.0m. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-K filed 2026-02-26, accession 0001628280-26-012237.Report this figure7.0Free cash flow, FY2024, twelve months to 2024-12-31. operating cash flow − capital expenditureOperating cash flow: $36.0m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2026-02-26, accession 0001628280-26-012237.Capital expenditure: $29.0m. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-K filed 2026-02-26, accession 0001628280-26-012237.Report this figure(93.0)Free cash flow, FY2025, twelve months to 2025-12-31. operating cash flow − capital expenditureOperating cash flow: −$27.0m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2026-02-26, accession 0001628280-26-012237.Capital expenditure: $66.0m. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-K filed 2026-02-26, accession 0001628280-26-012237.Report this figure

Focus or hover a figure to see its XBRL concept, period and filing; each links to that filing. A figure marked d is derived: a quarter computed from year-to-date figures, such as the fourth quarter as the fiscal year less the nine months before it. A ratio reads not reported when any input is missing.

Insider purchases and sales

All insider transactions

The last 20 open-market transactions reported on Form 4 (codes P and S). The reported price is the price per share the insider stated on the form: filing data, not a market price.

No open-market purchases or sales by insiders are in coverage from Nov 2024 to Oct 2026.

No open-market purchases or sales by insiders are in coverage for this company.

Funds that report holding it

All funds

From each manager's latest Form 13F, largest reported value first. Reported value is as filed at the quarter end: filing data, not a price. A put or call is an option position, not shares held.

Funds that report holding Indivior Pharmaceuticals, Inc.
FundQuarter endedReported valueSharesPut or callChange on the quarter before
BlackRock, Inc.2026-06-30$767.6m18,709,432Added+167,212
VANGUARD PORTFOLIO MANAGEMENT LLC2026-06-30$310.7m7,572,287Reduced−319,532
OAKTREE CAPITAL MANAGEMENT LP2026-06-30$251.4m6,127,212Reduced−856,890
VANGUARD CAPITAL MANAGEMENT LLC2026-06-30$225.5m5,495,486Reduced−91,090
STATE STREET CORP2026-06-30$204.8m4,992,071Added+88,078
FULLER & THALER ASSET MANAGEMENT, INC.2026-06-30$189.4m4,615,816Added+86,233
Two Seas Capital LP2026-06-30$142.8m3,479,493Reduced−1,267,017
MORGAN STANLEY2026-06-30$139.3m3,395,702Reduced−110,115
FRANKLIN RESOURCES INC2026-06-30$136.1m3,316,358Added+3,204,765
GEODE CAPITAL MANAGEMENT, LLC2026-06-30$129.7m3,159,866Added+234,178

Recent filings

All 544 filings

Reports and events: 10-K, 10-Q, 8-K, proxy statements and ownership schedules.

Indivior Pharmaceuticals, Inc., recent filings
FiledFormWhat it isAccession number
2026-10-2908:14 ET10-QQuarterly reportPeriod 2026-09-300001628280-26-068013
2026-10-2907:00 ET8-K2.02 Results of operations; 9.01 Financial statements and exhibits0001193125-26-436953
2026-10-1516:17 ET8-K5.07 Shareholder vote results0001104659-26-116253
2026-10-0607:15 ET8-K8.01 Other events0001104659-26-113883
2026-09-1707:18 ET8-K7.01 Regulation FD disclosure; 8.01 Other events; 9.01 Financial statements and exhibits0001104659-26-108417
2026-09-1516:28 ET8-K1.02 Termination of a material agreement; 9.01 Financial statements and exhibits0001625297-26-000028
2026-08-1317:30 ETSCHEDULE 13D/AOwnership report, active investor, amended0001140361-26-032874
2026-08-0316:24 ET10-QQuarterly reportPeriod 2026-06-300001628280-26-051895
2026-08-0308:32 ET8-K7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits0001193125-26-329618
2026-08-0306:50 ET8-K2.02 Results of operations; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits0001193125-26-329520

Latest annual report

Form 10-K for the fiscal year ended Dec 31, 2025Filed Feb 26, 2026. Its page lists the documents and the extracted sections, such as Business and Risk factors.

Forecast league

Q3 FY2026, the quarter ended 2026-09-30, has been scored from the reported figures.See the target

About the filer

CIK
1625297
Tickers
INDV
Exchange
Nasdaq
SIC code
2834 Pharmaceutical Preparations
Sector
Healthcare
Fiscal year ends
Dec 31
Incorporated in
DE
Filer category
Large accelerated filer
Former names
INDIVIOR PLC (to 2026-01-08)

Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 29, 2026, 08:21 ET. Listed shows no prices and gives no investment advice.